Methotrexat Ebewe

Methotrexate, the active ingredient in Methotrexat Ebewe, is an antimetabolite presented as an injectable solution for intravenous use. It is employed to manage rheumatoid arthritis, psoriasis, certain leukemias and solid tumours, and gestational trophoblastic disease.

GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is an antimetabolite used across several disease families, primarily inflammatory and oncologic conditions. - Rheumatoid arthritis: reduces disease activity and slows joint damage. - Psoriasis: improves skin lesions and decreases severity. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Osteosarcoma: part of multi‑agent chemotherapy regimens to control tumour growth. - Gestational trophoblastic disease: eradicates trophoblastic tissue and prevents recurrence.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Mucositis or mouth ulcers. - Fatigue or weakness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe infection due to immunosuppression. - Pulmonary toxicity, including interstitial pneumonitis. - Hepatotoxicity with potential fibrosis. - Renal toxicity, especially with high doses. - Secondary malignancies such as acute myeloid leukemia.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in pregnant or planning patients. - Renal function: assess baseline and adjust dosing if impairment is present. - Liver function: monitor transaminases regularly; avoid in severe hepatic disease. - Hematologic status: perform complete blood counts before and during therapy. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels and risk of toxicity. - Proton pump inhibitors (e.g., omeprazole): may reduce renal clearance and heighten adverse effects.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: can potentiate bone marrow suppression. - Phenytoin and other enzyme‑inducing anticonvulsants: may lower methotrexate concentrations. - Live vaccines: risk of infection due to immunosuppression.